Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
August 2025
The global infectious disease diagnostics market size was valued at US$ 25.01 billion in 2024 and is projected to grow to US$ 27.43 billion in 2025. Forecasts suggest it will reach approximately US$ 62.95 billion by 2034, registering a CAGR of 9.67% during the period.
The infectious disease diagnostics market is witnessing steady growth driven by the rising prevalence of viral and bacterial infections, increasing demand for rapid and accurate testing, and advancements in molecular and point-of-care diagnostic technologies. Growing awareness, supportive government initiatives, and expanding healthcare infrastructure further fuel market adoption. The market encompasses diverse testing methods, including PCR, immunoassays, and next-generation sequencing, catering to hospitals, clinics, and research laboratories worldwide.
| Table | Scope |
| Market Size in 2025 | USD 27.43 Billion |
| Projected Market Size in 2034 | USD 62.95 Billion |
| CAGR (2025 - 2034) | 9.67% |
| Leading Region | North America |
| Market Segmentation | By Product & Service, By Technology / Test Type, By Testing Setting, By Disease Type, By End-User, By Region |
| Top Key Players | Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, bioMérieux, Danaher (e.g. Cepheid, Beckman Coulter), Beckton Dickinson (BD), Siemens Healthineers, Bio-Rad Laboratories, QIAGEN, Hologic, Grifols, Adaptive Biotechnologies, Illumina, Quest Diagnostics, PerkinElmer, Sysmex Corporation, MedMira, Lucira Health, Seegene, Sherlock Biosciences |
The Infectious Disease Diagnostics Market encompasses tests, instruments, reagents, and software for detecting pathogens (viruses, bacteria, fungi, parasites) across clinical, point-of-care (POC), and public health settings. It includes molecular assays, immunodiagnostics (antigen/antibody tests), microbiology culture, sequencing, and rapid diagnostics, helping clinicians manage outbreaks, guide treatment, and monitor epidemiology globally. The market is evolving with the rise of rapid molecular testing, such as PCR and next-generation sequencing, which allows precise and timely pathogen detection. Point-of-care diagnostics, AI-powered data analysis, and digital health integration are improving real-time monitoring and clinical decision-making. Increased emphasis on early detection, outbreak management, and personalized treatment strategies is driving innovation and expanding the market's reach across healthcare and research settings worldwide.
For Instance,
Government Initiatives and Funding : Programs targeting disease surveillance, prevention, and control promote diagnostic development and use.
Advancements in Molecular Diagnostics : Techniques like PCR, next-generation sequencing, and CRISPR improve detection sensitivity and speed.
AI is transforming the infectious disease diagnostics market by enabling faster and more accurate analysis of complex clinical data. It supports early detection of infections, predictive outbreak modeling, and automated interpretation of molecular and imaging results. Integration of AI with point-of-care and laboratory diagnostics enhances decision-making, reduces human error, and improves patient outcomes, driving efficiency and expanding the adoption of advanced diagnostic solutions across healthcare settings.
Rising Prevalence of Infectious Diseases
The growing incidence of infectious diseases is propelling the infectious disease diagnostics market as healthcare systems require efficient tools to detect and manage infections promptly. Higher disease prevalence increases testing volumes in hospitals, clinics, and laboratories, driving demand for reliable diagnostics. Additionally, frequent outbreaks and emerging pathogens emphasize the need for rapid and accurate detection methods, encouraging the adoption of advanced diagnostic technologies and expanding the market across both developed and developing regions.
High Cost of Advanced Diagnostics Test
The elevated cost of modern diagnostic technologies poses a significant challenge for the infectious disease diagnostics market. Many healthcare facilities, particularly in low-and middle-income regions, face budget constraints that limit the adoption of advanced molecular and rapid testing solutions. High expenses for equipment, reagents, and skilled personnel make widespread implementation difficult, slowing the overall market expansion despite the growing need for accurate and timely detection of infectious diseases.
Advancements in Molecular and Point-of-Care Technologies
Innovations in molecular and point-of-care diagnostics offer promising opportunities in the infectious disease market by simplifying and accelerating pathogen detection. These technologies enable immediate testing at clinics or remote locations, minimizing delays in treatment and improving disease management. Enhanced sensitivity and specificity of modern molecular assays, combined with portable POC devices, expand access to critical diagnostics, support outbreak control, and strengthen healthcare response capabilities, making them a major growth avenue for the market in the future.
For Instance,
The reagents, kits & consumables segment leads the infectious disease diagnostics market due to their critical role in enabling consistent and reliable testing. As diagnostic procedures expand across hospitals, clinics, and laboratories, the repeated need for these supplies ensures sustained demand. Moreover, the rise of advanced molecular and rapid testing techniques increased the consumption of specialized reagents and kits, making the segment a key contributor to market growth and a central component of diagnostic workflows.
The instruments segment is anticipated to record the fastest growth in the infectious disease diagnostics market, driven by the rising need for sophisticated testing equipment in clinical and research laboratories. Innovations in automated analyzers, molecular testing platforms, and point-of-care devices enhance testing speed, accuracy, and efficiency. As healthcare providers prioritize rapid diagnosis and outbreak management, investment in advanced instruments increases, making this segment a significant contributor to market expansion during the forecast period.
In 2024, the immunodiagnostics segment dominated the infectious disease diagnostics market due to its ease of use, quick turnaround, and dependable results. These methods are widely implemented for detecting immune responses to infections and are suitable for both clinical labs and decentralized testing locations. The growing emphasis on early diagnosis and routine screening has further driven the adoption of immunodiagnostic technologies, securing their leading position in the market.
The molecular diagnostics segment is projected to experience the fastest growth in the infectious disease diagnostics market because of its precision and rapid detection capabilities. Healthcare providers increasingly rely on these techniques for identifying pathogens quickly and accurately, especially during outbreaks. Rising investments in molecular testing infrastructure, coupled with growing awareness of early and reliable disease detection, are accelerating adoption, making this segment a major driver of market expansion over the forecast period.
The laboratory-based testing segment dominated the infectious disease diagnostics market because clinical and high-throughput laboratories provide precise, reliable, and large-scale testing solutions. These facilities are equipped with advanced instruments and trained staff capable of handling complex assays, ensuring accurate detection of pathogens. Additionally, increasing requirements for routine screening, epidemiological surveillance, and confirmatory testing drive the continued reliance on laboratory-based diagnostics, making the market the leading contributor to market revenue.
The point-of-care (POC) testing segment is projected to grow rapidly as healthcare providers increasingly seek quick and accessible diagnostic solutions. Rapid antigen and antibody tests allow immediate detection of infectious diseases at clinics, pharmacies, and remote sites, minimizing delays in patient care. Rising awareness of early diagnosis, convenience of on-site testing, and the need to manage outbreaks efficiently are key factors driving the accelerated adoption and growth of POC testing in the market.
The respiratory infections segment led the infectious disease diagnostics market in 204 and is projected to grow rapidly due to the widespread incidence of illnesses like influenza, COVID-19, and respiratory syncytial virus (RSV). Rising awareness of early detection, the necessity for quick treatment, and the implementation of advanced molecular and rapid testing methods in hospitals and clinics are driving adoption. This combination of high disease burden and technological advancement positions respiratory diagnostics as a major growth driver in the market.
In 2024, the hospitals segment accounted for the largest revenue share in the infectious disease diagnostics market due to its capacity to provide extensive testing services and manage high patient volumes. With access to sophisticated diagnostic equipment and trained staff, hospitals can deliver rapid and accurate detection of infectious pathogens. The increasing focus on patient care, early disease identification, and outbreak management reinforces hospitals' role as key end-users, making them the dominant contributor to the market revenue.
The diagnostic laboratories segment is projected to witness lucrative growth in the infectious disease diagnostics market during the forecast period, driven by the need for accurate, large-scale testing and specialized analyses. These laboratories provide advanced equipment and skilled personnel capable of handling complex assays, making them essential for routine screening and outbreak surveillance. Increasing collaboration with healthcare providers, adoption of automated testing platforms, and rising demand for efficient, reliable diagnostic services are key factors fueling the expansion of the market.
In 2024, North America led the infectious disease diagnostics market because of its robust healthcare system, advanced laboratory infrastructure, and strong focus on technological innovation. High adoption of molecular and rapid diagnostic tools, combined with supportive government policies and funding for infectious disease surveillance, has boosted market growth. The presence of major diagnostic companies and rising awareness for early detection and treatment further contribute to the region’s leading position and substantial revenue share in the market.
The U.S. market is growing due to the rising prevalence of infectious diseases, increasing demand for rapid and accurate testing, and widespread adoption of advanced molecular and point-of-care diagnostic technologies. Strong healthcare infrastructure, continuous R&D investment, and government initiatives for disease surveillance and outbreak management further support market expansion. Additionally, growing awareness about early diagnosis and timely treatment is driving the uptake of diagnostic solutions across hospitals and laboratories.
The market in Canada is expanding as healthcare providers increasingly focus on the timely and precise detection of infections. Rising use of molecular, immunodiagnostic, and rapid testing technologies, supported by modern laboratory facilities and skilled personnel, is driving growth. Government programs promoting disease surveillance, increased funding for healthcare infrastructure, and heightened public awareness about early diagnosis and preventive measures further contribute to the market’s steady development across the country.
Asia-Pacific is expected to grow at a faster pace in the infectious disease diagnostics market during the forecast period due to the rising prevalence of infectious diseases, increasing healthcare expenditure, and expanding access to advanced diagnostic technologies. Rapidly improving healthcare infrastructure, growing awareness about early disease detection, and rising adoption of point-of-care and molecular testing in countries like China, India, and Japan are key growth drivers. Additionally, government initiatives and rising investments in laboratory facilities support market expansion in the region.
The market in China is increasing due to the rising prevalence of infectious diseases, growing demand for rapid and accurate testing, and expanding adoption of advanced molecular and immunodiagnostic technologies. Government support through healthcare initiatives, increased funding for disease surveillance, and investments in diagnostic infrastructure are further boosting market growth. Additionally, rising public awareness about early detection and the expansion of hospitals and laboratories contribute to the market’s steady expansion.
The market in India is witnessing strong growth due to rising population density and frequent outbreaks of infectious diseases. Expansion of private and public healthcare facilities, increasing availability of advanced diagnostic technologies, and government initiatives promoting health screening are driving demand. Additionally, growing awareness among patients about early detection and timely treatment, along with investments in modern laboratory infrastructure, is further accelerating the market’s development across the country.
Europe is approaching the market through significant investment in advanced molecular, immunodiagnostic, and point-of-care technologies to enhance early detection and management of infectious diseases. Strong healthcare infrastructure, stringent regulatory standards, and government-supported disease surveillance programs drive the adoption of innovative diagnostic solutions. Additionally, collaborations between biotech companies, research institutions, and hospitals, along with rising awareness of rapid and accurate testing, are fueling market growth across countries such as Germany, the U.K., and France.
The UK market is expanding as healthcare providers increasingly prioritize early and precise detection of infections. Rising adoption of innovative molecular, immunodiagnostic, and rapid testing technologies, supported by well-established laboratories and healthcare facilities, is fueling growth. Government initiatives for disease monitoring, public health campaigns, and investments in diagnostic infrastructure further enhance market development, while growing awareness among patients and clinicians about timely testing contributes to the sector’s steady advancement.
The market in Germany is expanding as the growing use of innovative testing technologies, including PCR, rapid antigen, and immunodiagnostic assays, enhances diagnostic accuracy and efficiency. Supportive government policies, investments in laboratory infrastructure, and increasing awareness about preventive healthcare and early disease identification are also driving market growth, positioning Germany as a leading player in Europe’s infectious disease diagnostics landscape.
In September 2024, F. Hoffmann-La Roche Ltd. (Switzerland) introduced the cobas Respiratory Flex Test, featuring its innovative TAGS (Temperature-Activated Generation of Signal) technology. This multiplex PCR-based test can detect up to 15 respiratory pathogens in a single run by integrating color, temperature, and data processing. Roche highlighted that many respiratory illnesses share similar symptoms, complicating diagnosis. CEO Matt Sause emphasized that TAGS technology enables faster, accurate identification of viruses, helping clinicians provide timely treatment and reduce transmission.
By Product & Service
By Technology / Test Type
By Testing Setting
By Disease Type
By End-User
By Region
August 2025
August 2025
July 2025
July 2025